Clinicopathological analysis of oral diffuse large B-cell lymphoma, NOS: A systematic review

Author(s)

Rodrigues-Fernandes, Carla Isabelly ^[1] ; de Souza, Lucas Lacerda ^[2] ; dos Santos-Costa, Sara Ferreira ^[3] ; Rebelo Pontes, Helder Antonio ^[2] ; de Almeida, Oslei Paes ^[1] ; Vargas, Pablo Agustin ^[1] ; Henao, Javier Rendon ^[4] ; Rahimi, Siavash ^[5] ; Brennan, Peter A. ^[6] ; Fonseca, Felipe Paiva ^{[1, 3]}

Affiliation

^[1] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Oral Diag, Piracicaba - Brazil

^[2] Fed Univ Para, Joao de Barros Barreto Univ Hosp, Serv Oral Pathol, Belem, Para - Brazil

^[3] Univ Fed Minas Gerais, Sch Dent, Dept Oral Surg & Pathol, Belo Horizonte, MG - Brazil

^[4] Univ Antioquia, Med Sch, Medellin - Colombia

^[5] Queen Alexandra Hosp, Dept Histopathol, Portsmouth, Hants - England

^[6] Queen Alexandra Hosp, Dept Oral & Maxillofacial Surg, Portsmouth, Hants - England

• Document type: Review article
• Source: JOURNAL OF ORAL PATHOLOGY & MEDICINE; v. 48, n. 3, p. 185-191, MAR 2019.
• Web of Science Citations: 1

Abstract

Background Diffuse large B-cell lymphoma, NOS (DLBCL NOS) is the commonest extranodal non-Hodgkin lymphoma diagnosed in the oral and maxillofacial region. However, few studies are currently available and its prognostic determinants remain undefined. Purpose To analyse the available data on oral DLBCL NOS and to describe its clinicopathological features, identifying potential prognostic factors. Methods An electronic systematic search was performed using multiple databases with a specific search strategy in April 2018. All reports describing DLBCL NOS involving the oral cavity and jaw bones with sufficient clinicopathological information were assessed. Results Sixty-three publications were included in the study, comprising 122 cases. Oral DLBCL NOS was found predominantly in elderly males (61.5%), and most often presented as an asymptomatic swelling of the gingiva. Patients commonly were HIV-negative (36.1%), with few reports describing EBV-positive cases (four cases/3.3%). Only eight cases presented B symptoms and most cases were classified as stage I or II (48.4%). CHOP therapy was the main treatment option (24.5%) and the overall 5-year survival rate achieved 83%. Males and advanced Ann Arbor stage patients presented significantly lower survival rates in the univariate analysis, but no significance was found in the multivariate model. Conclusion Oral DLBCL NOS is an aggressive malignancy, but with a high survival rate. (AU)

• FAPESP's process: 17/14880-3 - Clinicopathological and immunohistochemical analysis of follicular lymphoid hyperplasias and lymphomas of the oral cavity
• Grantee: Oslei Paes de Almeida
• Support Opportunities: Regular Research Grants